SEBASTIAN G SCHNEEWEISS

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis
    Seo Young Kim
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Arthritis Res Ther 12:R154. 2010
  2. pmc The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28
    Masayo Sato
    Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Arthritis Res Ther 8:R57. 2006
  3. pmc Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study
    Gladys Ting
    Department of Medicine, Division of Pharmacoepidemiology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Arthritis Res Ther 10:R95. 2008
  4. pmc The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women s Hospital in Boston, Massachusetts, USA
    Health Aff (Millwood) 28:w305-16. 2009
  5. ncbi request reprint Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA
    Circulation 115:2128-35. 2007
  6. ncbi request reprint Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Cancer Causes Control 18:561-9. 2007
  7. ncbi request reprint Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Arch Intern Med 167:847-52. 2007
  8. ncbi request reprint Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Arthritis Rheum 56:1754-64. 2007
  9. ncbi request reprint Repeated hospitalizations predict mortality in the community population with heart failure
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02130, USA
    Am Heart J 154:260-6. 2007
  10. ncbi request reprint Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis
    Niteesh K Choudhry
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Health Aff (Millwood) 26:186-94. 2007

Detail Information

Publications66

  1. pmc Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis
    Seo Young Kim
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Arthritis Res Ther 12:R154. 2010
    ..Although osteoporosis has been reported to be more common in patients with rheumatoid arthritis (RA), little is known whether the risk of osteoporotic fractures in these patients differs by age, sex, and anatomic site...
  2. pmc The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28
    Masayo Sato
    Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Arthritis Res Ther 8:R57. 2006
    ..The RARBIS has both face and convergent validity for patients with RA and relevant subgroups and may have application for medical records studies in patients with RA...
  3. pmc Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study
    Gladys Ting
    Department of Medicine, Division of Pharmacoepidemiology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Arthritis Res Ther 10:R95. 2008
    ....
  4. pmc The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women s Hospital in Boston, Massachusetts, USA
    Health Aff (Millwood) 28:w305-16. 2009
    ..Patients reaching the Part D coverage gap (12 percent) experienced a decrease in essential medication use ranging from 5.7 percentage points per month for warfarin to 6.3 percentage points for statins...
  5. ncbi request reprint Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA
    Circulation 115:2128-35. 2007
    ....
  6. ncbi request reprint Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Cancer Causes Control 18:561-9. 2007
    ..However, linkage between cancer registry and claims data including pharmacy-dispensing information is not always available. We examined the accuracy of claims-based definitions of incident cancers and their date of diagnosis...
  7. ncbi request reprint Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Arch Intern Med 167:847-52. 2007
    ....
  8. ncbi request reprint Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Arthritis Rheum 56:1754-64. 2007
    ..To assess the association between the initiation of anti-tumor necrosis factor alpha (anti-TNFalpha) therapy and the risk of serious bacterial infections in routine care...
  9. ncbi request reprint Repeated hospitalizations predict mortality in the community population with heart failure
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02130, USA
    Am Heart J 154:260-6. 2007
    ..The impact of repeated heart failure (HF) hospitalization on mortality has not been studied for a large community population with HF. We aimed to characterize survival of patients in relation to the number of HF hospitalizations...
  10. ncbi request reprint Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis
    Niteesh K Choudhry
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Health Aff (Millwood) 26:186-94. 2007
    ..Our analysis suggests that covering combination therapy for such patients will save both lives and money...
  11. ncbi request reprint Statins and the risk of lung, breast, and colorectal cancer in the elderly
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02130, USA
    Circulation 115:27-33. 2007
    ..Long-term statin users tend to be healthier, less frail, and more adherent to therapy than nonusers, however. This could explain such apparent "protective" effects...
  12. ncbi request reprint Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis
    Daniel H Solomon
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Arthritis Rheum 54:3790-8. 2006
    ..This study was undertaken to investigate the effects of various immunosuppressive medications on the risk of cardiovascular events among a group of older patients with RA...
  13. pmc Angiotensin inhibition after myocardial infarction: does drug class matter?
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
    J Gen Intern Med 21:1242-7. 2006
    ..Little is known about their relative use after MI in typical care settings, and about their relative effectiveness outside the clinical trial setting...
  14. ncbi request reprint Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis
    Sebastian Schneeweiss
    Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA 021205, USA
    Arthritis Rheum 54:3390-8. 2006
    ....
  15. ncbi request reprint Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02130, USA
    Arthritis Rheum 54:2757-64. 2006
    ..This study was undertaken to estimate the association between treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and development of cancer in patients with RA...
  16. ncbi request reprint Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma
    Colin R Dormuth
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Ther 28:964-78; discussion 962-3. 2006
    ..Evaluations of drug cost-sharing policies within the same population are needed for a fair comparison of different options...
  17. ncbi request reprint Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal
    Gabriela Schmajuk
    Stanford University, Palo Alto, California, USA
    Arthritis Rheum 57:928-34. 2007
    ..Our objective was to determine the rate and predictors of DMARD use in a cohort of elderly patients with RA...
  18. ncbi request reprint Analysis of factors associated with statin adherence in a hierarchical model considering physician, pharmacy, patient, and prescription characteristics
    Alexander Pedan
    Analytical Services, Adheris, Inc, One Van de Graaff Dr, Burlington, MA 01803, USA
    J Manag Care Pharm 13:487-96. 2007
    ..Adherence with maintenance drug therapy such as HMG-CoA reductase inhibitors (statins) is typically analyzed from the perspective of patient characteristics...
  19. pmc Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St Ste 3030, Boston, MA 02120, USA
    Am J Manag Care 13:445-52. 2007
    ....
  20. pmc Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups
    Daniel H Solomon
    Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
    Arthritis Rheum 59:1097-104. 2008
    ..There is substantial concern regarding the potential cardiovascular adverse effects of selective coxibs and nonselective NSAIDs, but many patients with arthritis experience important clinical benefits from these agents...
  21. pmc Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis
    Soko Setoguchi
    Divisions of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard MedicalSchool, Boston, MA 02130, USA
    Am Heart J 156:336-41. 2008
    ..Although TNFAs had significant benefits in treating rheumatoid arthritis (RA), little is known whether the drugs pose an increased risk of HF in older patients with RA...
  22. pmc Does knowledge of medication prices predict physicians' support for cost effective prescribing policies
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA, USA
    Can J Clin Pharmacol 15:e286-94. 2008
    ..Years after implementation, these policies remain controversial among physicians...
  23. pmc Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications
    Colin R Dormuth
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Ther 30:1038-50. 2008
    ..Objective: The aim of this study was to compare the effects of 2 recent cost-sharing policies on emergency hospitalizations due to chronic obstructive pulmonary disease, asthma, or emphysema (CAE), and on physician visits...
  24. pmc Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies
    Niteesh K Choudhry
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Am Heart J 156:31-6. 2008
    ..Removing patient out-of-pocket drug costs may increase adherence, improve clinical outcomes, and even reduce overall health costs for high-risk patients. The existing data are inadequate to assess whether this strategy is effective...
  25. doi request reprint The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence
    Daniel H Solomon
    Brigham and Women s Hospital, Division of Rheumatology, Immunology and Allergy, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Arthritis Rheum 58:919-28. 2008
  26. pmc The impact of cost sharing on antidepressant use among older adults in British Columbia
    Philip S Wang
    National Institute of Mental Health, Bethesda, MD 20892 9629, USA
    Psychiatr Serv 59:377-83. 2008
    ....
  27. pmc Evaluating uses of data mining techniques in propensity score estimation: a simulation study
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02130, USA
    Pharmacoepidemiol Drug Saf 17:546-55. 2008
    ....
  28. pmc A cross-national study of the persistence of antihypertensive medication use in the elderly
    Boris L G Van Wijk
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands b l g
    J Hypertens 26:145-53. 2008
    ..The aim of this study was to describe and compare patterns of use of antihypertensive drugs in a population of elderly patients in the United States (Pennsylvania), Canada (British Columbia) and the Netherlands...
  29. ncbi request reprint Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications
    Philip S Wang
    J Clin Psychopharmacol 27:707-10. 2007
  30. ncbi request reprint Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluations
    Malcolm Maclure
    School of Health Information Science, University of Victoria, Victoria, British Columbia, Canada
    Med Care 45:S44-9. 2007
    ..Centralized administrative databases enable low-cost pragmatic randomized trials (PRTs) of drug effectiveness and safety. We simplified the PRT strategy by using designed delays (DD) to evaluate drug policies...
  31. pmc Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Med Care 45:S131-42. 2007
    ..The goal of restricting study populations is to make patients more homogeneous regarding potential confounding factors and treatment effects and thereby achieve less biased effect estimates...
  32. ncbi request reprint Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects?
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts, USA
    Med Care 45:S116-22. 2007
    ..We sought to explore the validity of physician-level IV in a comparative study of short-term mortality risk among elderly users of conventional versus atypical antipsychotic medications (APM)...
  33. ncbi request reprint Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review
    Michael A Fischer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
    Med Care 44:658-63. 2006
    ..However, the evidence base for the prior authorization criteria has not been examined previously...
  34. ncbi request reprint Assessing health state utilities in elderly patients at cardiovascular risk
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Med Decis Making 26:247-54. 2006
    ..Health state preferences can be a crucial component of cost-effectiveness analyses, but off-the-shelf health state utilities specifically for older people are not available...
  35. ncbi request reprint Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk
    Daniel H Solomon
    Division of Pharmacoepidemiology, Brigham and Women s Hospital, Boston, Massachusetts 02120, USA
    Arthritis Rheum 54:1378-89. 2006
    ..This study was undertaken to examine, in a large group of new users of coxibs and NSAIDs, the rate of cardiovascular events, their time course, and whether baseline cardiovascular risk modified the rate ratios (RRs) for future events...
  36. pmc Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Gigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    J Gen Intern Med 19:444-50. 2004
    ..We sought to evaluate and rank the performance of comorbidity scores across selected U.S. and Canadian elderly populations using health care utilization databases...
  37. ncbi request reprint Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults
    Daniel H Solomon
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, Mass 02120, USA
    Circulation 109:2068-73. 2004
    ..We studied the relative risk of acute myocardial infarction (AMI) among users of celecoxib, rofecoxib, and NSAIDs in Medicare beneficiaries with a comprehensive drug benefit...
  38. ncbi request reprint Use of the case-crossover design to study prolonged drug exposures and insidious outcomes
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Ann Epidemiol 14:296-303. 2004
    ..We investigated whether case-crossover methods can be used to study prolonged exposures and insidious outcomes...
  39. pmc Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations
    Sebastian Schneeweiss
    Brigham and Women s Hospital and Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, 1620 Tremont St Suite 3030, Boston, MA 02120, USA
    BMJ 328:560. 2004
    ..To compare the results of a randomised and an observational evaluation of the same policy that restricted reimbursement for nebulised respiratory medications in adult patients in a community setting...
  40. ncbi request reprint Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?
    Daniel H Solomon
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Med 115:715-20. 2003
    ..We examined the relative effects of patient risk factors for gastrointestinal toxicity, other patient characteristics, and physician prescribing preferences on the decision to prescribe a selective COX-2 inhibitor...
  41. pmc Improved comorbidity adjustment for predicting mortality in Medicare populations
    Sebastian Schneeweiss
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Health Serv Res 38:1103-20. 2003
    ..To define and improve the performance of existing comorbidity scores in predicting mortality in Medicare enrollees...
  42. ncbi request reprint Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia
    Margreet S Duetz
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Ther 25:273-84. 2003
    ..Gender-specific attitudes and communication styles are known to influence both the content and outcome of medical visits. Therefore, gender-specific differences in response to cost containment may also occur...
  43. ncbi request reprint European healthcare policies for controlling drug expenditure
    Silvia M Ess
    Hirslanden Research, Zurich, Switzerland
    Pharmacoeconomics 21:89-103. 2003
    ..Policies intended to affect physicians' prescribing behaviour include guidelines, information (about price and less expensive alternatives) and feedback, and the use of budgetary restrictions...
  44. ncbi request reprint Metric properties of the appropriateness evaluation protocol and predictors of inappropriate hospital use in Germany: an approach using longitudinal patient data
    Oliver Sangha
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Int J Qual Health Care 14:483-92. 2002
    ..Attempts at quality improvement need to relate costs to outcomes. Until now, there has been no standardized methodology to evaluate the appropriateness of hospital care...
  45. ncbi request reprint Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial
    Jerry Avorn
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Control Clin Trials 23:757-73. 2002
    ....
  46. ncbi request reprint Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance
    Sebastian Schneeweiss
    Divison of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Ave BLI 341, Boston, MA 02115, USA
    J Clin Epidemiol 55:833-41. 2002
    ..Results from nonrandomized comparisons of subgroups defined by their compliance to a policy change should generally be interpreted cautiously, and several biases should be explored...
  47. ncbi request reprint Clozapine use and risk of diabetes mellitus
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Psychopharmacol 22:236-43. 2002
    ..Additional data from pharmacoepidemiologic studies and randomized controlled trials are needed to exclude the possibility of residual confounding and ensure the appropriate use of this agent...
  48. pmc Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization
    Sebastian Schneeweiss
    Department of Epidemiology, Harvard School of Public Health, Boston, Mass, USA
    CMAJ 166:737-45. 2002
    ..The objective of this study was to analyze the effect of reference-based pricing of angiotensin-converting enzyme (ACE) inhibitors on drug utilization, cost savings and potential substitution with other medication classes...
  49. ncbi request reprint Prescription duration after drug copay changes in older people: methodological aspects
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Ave, Boston, MA 02115, USA
    J Am Geriatr Soc 50:521-5. 2002
    ..Reference pricing, a copayment for expensive medications above a fixed limit, for angiotensin-converting enzyme(ACE) inhibitors in older British Columbia residents, is used as a case example...
  50. ncbi request reprint Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    Med Care 42:653-60. 2004
    ..Critics argued that drug plan savings are offset by administrative costs and increased spending on other health services...
  51. ncbi request reprint Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records
    Yuka Kiyota
    Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, Mass USA
    Am Heart J 148:99-104. 2004
    ....
  52. pmc Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02120, USA
    Epidemiology 17:268-75. 2006
    ..Instrumental variable methods have been proposed as a potential approach to control confounding by indication in nonexperimental studies of treatment effects; however, good instruments are hard to find...
  53. ncbi request reprint Measuring prescribing improvements in pragmatic trials of educational tools for general practitioners
    Malcolm Maclure
    School of Health Information Science, Faculty of Human and Social Development, University of Victoria, British Columbia BC, Canada
    Basic Clin Pharmacol Toxicol 98:243-52. 2006
    ..A decade of progress on methods for evaluating prescribing improvement programs with drug claims data has enabled planning of routine randomized pragmatic trials of education and policies in primary care in Canada...
  54. ncbi request reprint A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Clin Pharmacol Ther 79:379-88. 2006
    ..We evaluated the clinical and economic consequences of coverage restriction for 3 leading proton pump inhibitors (PPIs) in a large-scale natural experiment...
  55. ncbi request reprint Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Kidney Dis 46:1080-7. 2005
    ..However, little is known about the adequacy of adherence to these guidelines in elderly patients with diabetes and predictors of such appropriate ACE-inhibitor or ARB use...
  56. ncbi request reprint Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model
    Roy H Perlis
    Pharmacogenomics Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 25:427-34. 2005
    ..More consistent reporting of test parameters such as sensitivity and specificity would greatly facilitate assessment of future pharmacogenetic studies...
  57. ncbi request reprint Performance of a rheumatoid arthritis records-based index of severity
    Gladys Ting
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    J Rheumatol 32:1679-87. 2005
    ..To assess the performance of a rheumatoid arthritis (RA) records-based index of severity (RARBIS) developed by a Delphi panel process in a cohort of patients with RA...
  58. ncbi request reprint Identification of individuals with CKD from Medicare claims data: a validation study
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Am J Kidney Dis 46:225-32. 2005
    ..The validity of this approach to identify patients with CKD has not been sufficiently studied...
  59. ncbi request reprint Sudden uncontrollable somnolence and medication use in Parkinson disease
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Arch Neurol 62:1242-8. 2005
    ....
  60. ncbi request reprint Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Hypertension 46:273-9. 2005
    ..Highly prevalent, noncardiovascular conditions appear to deter use of antihypertensives in elderly with hypertension...
  61. ncbi request reprint A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 58:98-102. 2005
    ..We sought to quantify the relative contributions of patient vs. physician factors to the decision to prescribe selective cyclooxygenase-2 (COX-2) inhibitors during the first 2 years of their availability...
  62. ncbi request reprint Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Epidemiology 16:17-24. 2005
    ..We show how to assess the impact of confounding by factors not measured in Medicare claims data in a study of the association between selective COX2 inhibitors and acute myocardial infarction (MI)...
  63. ncbi request reprint Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors
    Michael A Fischer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    N Engl J Med 351:2187-94. 2004
    ..To control these expenses, many state Medicaid programs have implemented prior-authorization requirements before coxibs can be prescribed. We evaluated the effect of such programs on the use of coxibs by Medicaid beneficiaries...
  64. ncbi request reprint Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarction
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
    Am J Cardiol 94:415-20. 2004
    ..Thus, in patients with AMI, earlier presentation to the hospital and more rapid initiation of thrombolysis could prevent significant decreases in functional status months after the initial infarct...
  65. ncbi request reprint Relationship between COX-2 specific inhibitors and hypertension
    Daniel H Solomon
    Division of Pharmacoepidemiology, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02120, USA
    Hypertension 44:140-5. 2004
    ..1; 95% CI, 1.0 to 4.3). In this retrospective case-control study of patients aged > or =65 years, rofecoxib use was associated with an increased relative risk of new onset hypertension; this was not seen in patients taking celecoxib...
  66. ncbi request reprint Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 346:822-9. 2002
    ..Although reference pricing may reduce the costs of prescription drugs, there is concern that patients may switch to less effective medications or stop treatment...

Research Grants17

  1. Analyzing Complex Healthcare Data to Determine Causality of Observed Drug Effects
    SEBASTIAN G SCHNEEWEISS; Fiscal Year: 2010
    ..The theoretical foundation and the ready-to-use algorithms will likely lead to a fundamental shift in how databases contribute to the fast and accurate assessment of newly-marketed medications. ..
  2. Impact of Medicare Drug Coverage on Antidepressant Quality and Outcomes
    Sebastian Schneeweiss; Fiscal Year: 2007
    ..g., to formulary, cost-sharing, and MTM programs) be made to improve the quality and outcomes of pharmacotherapies in susceptible and traditionally under-served elderly with depression. ..
  3. Antidepressant Use and Suicidality: Comparative Safety in Children and Adults
    Sebastian Schneeweiss; Fiscal Year: 2007
    ....
  4. Consequences of Drug Cost Sharing:A New Randomized Trial
    Sebastian Schneeweiss; Fiscal Year: 2006
    ..It should further provide a set of refined tools describing how to plan, implement, and execute drug cost-saving measures, including a pre-policy impact-simulation software. ..
  5. Effects of income-based drug charges on older Patients
    Sebastian Schneeweiss; Fiscal Year: 2006
    ..abstract_text> ..
  6. CONSEQUENCES OF DRUG COST SHARING IN THE ELDERLY
    Sebastian Schneeweiss; Fiscal Year: 2002
    ..Additional analyses will examine possible changes in prescribing patterns for persons initiating ACEI or CCB treatment. ..